To overcome barriers to biologic care for patients with asthma, personalized treatment is key, according to a speaker at the 16th Annual Allergy, Asthma & Immunology CME Conference.

According to a real-world study, tezepelumab is an effective add-on biologic with a rapid onset of action for patients with both T2-high and T2-low severe asthma. The study was published ...

Patients also had a median of two exacerbations per year before biologic treatment, 57.1% (n = 1,129 of 1,978) had used long-term oral corticosteroids (LTOCS) and 74.2% (n = 1,005 of 1,355) had ...

In summary, the future of asthma treatment lies in the fusion of scientific innovation and holistic care. With continued research and patient-centered solutions, AMSA Biotech is committed to ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of targeted drugs are currently available, including lebrikizumab, dupilumab, and ...

Adherence to biologic agents for the treatment of moderate to severe asthma varies, ... Cite this: Pam Harrison. Adherence to Asthma Biologics Depends on Site of Treatment - Medscape - Jun 09, 2022.

Biologics used as an asthma treatment also appear to improve symptoms of coexisting chronic rhinosinusitis in some patients, according to results from a real-world study published in the ...

The introduction of new biological therapies and advancements in biomarkers have paved the way for more targeted and personalized treatment options for the treatment of severe asthma. Currently ...

When compared to high-dose ICS treatment paired with a placebo, the monoclonal antibody with medium-dose ICS treatment reduced severe asthma exacerbations by 70% (0.273 vs 0.899 per year, P<0.0001 ...

Patients with uncontrolled asthma who do not adhere to treatment may be escalated to biologics before maintenance therapy efficacy can be assessed.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...